43.77
1.77%
0.835
Schlusskurs vom Vortag:
$42.93
Offen:
$45.07
24-Stunden-Volumen:
231.91K
Relative Volume:
0.50
Marktkapitalisierung:
$2.94B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-11.64
EPS:
-3.76
Netto-Cashflow:
$-157.31M
1W Leistung:
-12.02%
1M Leistung:
-15.33%
6M Leistung:
-0.07%
1J Leistung:
+84.66%
Merus N V Stock (MRUS) Company Profile
Firmenname
Merus N V
Sektor
Branche
Telefon
31 030 253 8800
Adresse
YALELAAN 62, 3584 CM UTRECHT
Vergleichen Sie MRUS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
MRUS | 43.65 | 2.94B | 35.93M | -244.56M | -157.31M | -3.76 |
VRTX | 447.18 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 741.71 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 589.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.84 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.36 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Merus N V Stock (MRUS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-11-02 | Eingeleitet | Canaccord Genuity | Buy |
2023-08-21 | Eingeleitet | TD Cowen | Outperform |
2022-08-02 | Eingeleitet | Stifel | Buy |
2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
2022-02-10 | Eingeleitet | Needham | Buy |
2021-11-17 | Fortgesetzt | Guggenheim | Buy |
2021-06-07 | Hochstufung | Citigroup | Neutral → Buy |
2021-04-08 | Eingeleitet | William Blair | Outperform |
2021-03-16 | Eingeleitet | SVB Leerink | Outperform |
2020-06-26 | Eingeleitet | H.C. Wainwright | Buy |
2020-05-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2019-11-20 | Fortgesetzt | Guggenheim | Buy |
2019-06-28 | Eingeleitet | ROTH Capital | Buy |
2019-04-12 | Fortgesetzt | Guggenheim | Buy |
2019-04-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2019-03-27 | Eingeleitet | Berenberg | Buy |
2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
2017-03-21 | Herabstufung | Citigroup | Buy → Neutral |
2016-12-22 | Hochstufung | Citigroup | Neutral → Buy |
2016-11-07 | Herabstufung | Citigroup | Buy → Neutral |
2016-06-13 | Eingeleitet | Citigroup | Buy |
2016-06-13 | Eingeleitet | Guggenheim | Buy |
2016-06-13 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Merus N V Aktie (MRUS) Neueste Nachrichten
The Goldman Sachs Group Initiates Coverage on Merus (NASDAQ:MRUS) - MarketBeat
Merus initiated with a Buy at Goldman Sachs - TipRanks
Needham & Company LLC Reaffirms Buy Rating for Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Shares Sold by First Turn Management LLC - MarketBeat
37,426 Shares in Merus (NASDAQ:MRUS) Acquired by State of New Jersey Common Pension Fund D - Defense World
Merus is Now Oversold (MRUS) - Nasdaq
GSA Capital Partners LLP Purchases Shares of 13,502 Merus (NASDAQ:MRUS) - MarketBeat
2,054 Shares in Merus (NASDAQ:MRUS) Purchased by US Bancorp DE - Defense World
Commodore Capital LP Bolsters Stake in Merus NV - GuruFocus.com
SAMLYN CAPITAL, LLC Bolsters Stake in Merus NV - GuruFocus.com
(MRUS) Trading Report - Stock Traders Daily
Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025? - MSN
FMR LLC Bolsters Stake in Merus NV - GuruFocus.com
10 Top Performing European Stocks Heading into 2025 - Insider Monkey
Merus (NASDAQ:MRUS) Shares Bought by TimesSquare Capital Management LLC - MarketBeat
US FDA extends review of Merus' gene-targeting cancer therapy - MSN
Merus (NASDAQ:MRUS) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Merus (NASDAQ:MRUS) Receives $86.70 Consensus Price Target from Brokerages - MarketBeat
MRUSMerus N.V. Common Shares Latest Stock News & Market Updates - StockTitan
Merus to Present at Upcoming Investor Conferences - The Manila Times
Merus Receives FDA extension of PDUFA for zenocutuzumab - GlobeNewswire
FDA extends review date for Merus' cancer drug Zeno By Investing.com - Investing.com Canada
FDA extends review date for Merus' cancer drug Zeno - Investing.com India
Merus (NASDAQ:MRUS) Shares Gap DownHere's Why - MarketBeat
Merus: Petosemtamab Set Up For December 2024 Data Presentation (NASDAQ:MRUS) - Seeking Alpha
FDA extends review period for Merus's cancer drug Zeno - Investing.com India
Merus : FDA Extends Review of Cancer Drug Zenocutuzumab to February - Marketscreener.com
US FDA extends review of Merus’ gene-targeting cancer therapy - PharmaLive
Merus says FDA extended review period for cancer drug - MSN
Merus stock slips as FDA delays drug review (MRUS:NASDAQ) - Seeking Alpha
FDA extends review period for Merus's cancer drug Zeno By Investing.com - Investing.com Canada
Harbor Capital Advisors Inc. Buys New Holdings in Merus (NASDAQ:MRUS) - MarketBeat
abrdn plc Invests $4.36 Million in Merus (NASDAQ:MRUS) - MarketBeat
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Merus sees cash runway into 2028 - MSN
Merus reports Q3 EPS ($1.46), consensus (88c) - MSN
Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.
Merus (NASDAQ:MRUS) Receives "Buy" Rating from Needham & Company LLC - MarketBeat
Merus N.V. Reports Q3 2024 Financial Results - TipRanks
Merus falls after updated data for lung cancer therapy - MSN
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update - GlobeNewswire
Novo Holdings A S Increases Position in Merus (NASDAQ:MRUS) - MarketBeat
Merus (NASDAQ:MRUS) Coverage Initiated at UBS Group - Defense World
UBS sees upside in Merus stock, highlights potential in head and neck cancer treatment - Investing.com India
Finanzdaten der Merus N V-Aktie (MRUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Merus N V-Aktie (MRUS) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Shuman Harry | VP Controller, PAO |
Aug 20 '24 |
Sale |
54.00 |
2,500 |
135,000 |
7,002 |
Silverman Peter B. | COO & GC |
Jun 27 '24 |
Option Exercise |
17.94 |
10,000 |
179,400 |
10,000 |
Silverman Peter B. | COO & GC |
Jun 27 '24 |
Sale |
60.00 |
10,000 |
600,000 |
0 |
Silverman Peter B. | COO & GC |
Jun 17 '24 |
Option Exercise |
24.36 |
62,000 |
1,510,280 |
62,000 |
Silverman Peter B. | COO & GC |
Jun 17 '24 |
Sale |
56.52 |
62,000 |
3,504,178 |
0 |
Shuman Harry | VP Controller, PAO |
Jun 12 '24 |
Sale |
57.84 |
7,300 |
422,232 |
7,002 |
Shuman Harry | VP Controller, PAO |
Jun 10 '24 |
Sale |
53.22 |
1,000 |
53,224 |
7,002 |
Shuman Harry | VP Controller, PAO |
Jun 04 '24 |
Sale |
52.89 |
6,000 |
317,354 |
7,002 |
Shuman Harry | VP Controller, PAO |
Dec 19 '23 |
Sale |
26.68 |
115 |
3,068 |
7,002 |
Silverman Peter B. | COO & GC |
Dec 15 '23 |
Sale |
25.00 |
22,386 |
559,650 |
0 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):